CCO Independent Conference Coverage

2006 Annual Meeting of the European Association for the Study of the Liver*

April 26-30, 2006 | Vienna, Austria

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Updates in HBV Management

Track 1 of 2

Faculty:
	Yves Benhamou, MD, PhD Geoffrey M. Dusheiko, MD, FCP(SA), FRCP Daniel Shouval, MD

Improving HCV Therapy in 2006

Track 2 of 2

Capsule Summaries

Expert Analysis

Faculty:
	Nezam H. Afdhal, MD, FRCPI Peter Ferenci, MD Stephanos J. Hadziyannis, MD

Expert Highlights

Listen to the experts quickly summarize the key issues in viral liver disease highlighted at the conference!

These audio files are in mp3 format. To listen to the audio, simply click "Download Audio." You must be logged on to the clinicaloptions.com site to listen to or download the mp3 files.

Yves Benhamou, MD, provides a perspective on improvements in hepatitis B virus therapy and future directions in the field. (6 minutes)

Download Audio

Stephanos J. Hadziyannis, MD, discusses the principles and practice behind the most important presentations in hepatitis C virus and hepatitis B virus management at EASL. (4 minutes)

Download Audio

CCO Slidesets

Updates in HBV Management

Format: Microsoft PowerPoint (.ppt) | File size: 595 KB

Advances in Viral Hepatitis

Format: Microsoft PowerPoint (.ppt) | File size: 326 KB

CCO Daily News (Not required for CME credit)

April 27, 2006

Retreatment with pegylated interferon alfa-2a plus ribavirin effective in previous HCV infected nonresponders to pegylated interferon alfa-2b plus ribavirin

April 30, 2006

CPG 10101 shows promising activity in refractory patients infected with chronic HCV

April 27, 2006

April 28, 2006

April 30, 2006

Entecavir superior to lamivudine for improving advanced fibrosis in patients with chronic hepatitis B

April 29, 2006

Efficacy of entecavir superior to lamivudine in nucleoside-naive patients with chronic hepatitis B

April 28, 2006

Telbivudine more effective than adefovir at 24 weeks in HBeAg-positive patients with chronic hepatitis B

April 29, 2006

African Americans show differences compared with whites in HCV genotype frequency and response

April 27, 2006

LB80380 efficacy and tolerability in HBeAg-positive patients with lamivudine-resistant HBV

May 1, 2006

24 weeks of peginterferon alfa-2a plus ribavirin more effective than 16 weeks in patients with HCV genotype 2 or 3

April 30, 2006

Combination treatment with VX-950 plus peginterferon alfa-2a highly potent, well tolerated in treatment-naive patients with HCV genotype 1

April 29, 2006

April 27, 2006

24-week treatment regimen with peginterferon alfa-2a plus ribavirin in HCV genotype 1 or 4 “superresponders” may offer an effective treatment option

April 29, 2006

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.